Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5  years

Eur J Obstet Gynecol Reprod Biol. 2024 Apr 6:S0301-2115(24)00168-4. doi: 10.1016/j.ejogrb.2024.04.001. Online ahead of print.ABSTRACTSmall cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but highly aggressive ovarian malignant neoplasm lacking a unified clinical management process. Most patients are diagnosed at an advanced stage and have an extremely poor prognosis with an overall probability of survival less than 10 %. Here, we describe the case of a patient with advanced SCCOHT achieved a survival of over 5 years after receiving multiple cycles of immunotherapy combined with anti-angiogenic therapy or CDK4/6 inhibitors. At the same time, we also summarized the case reports and clinical trials of immunotherapy in SCCOHT.PMID:38604920 | DOI:10.1016/j.ejogrb.2024.04.001
Source: Reproductive Biology - Category: Reproduction Medicine Authors: Source Type: research